GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
L

Lana Medical Company CJSC 9587.SR · SAR

N/A · Tadawul · 🇸🇦 Saudi Arabia

Compare

1.60

—

Close of 9 Nov 2026, in SAR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in SAR, from our data supplier.

FY2025

Revenue

SAR 92.3m

FY2018FY2025

Net income

SAR 2.7m

FY2018FY2025

Free cash flow

−SAR 10.4m

FY2018FY2025

Shareholders' equity

SAR 65.1m

FY2018FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
RevenueSAR 92.3mSAR 84.1mSAR 48.6mSAR 40.8mSAR 32.0mSAR 21.1mSAR 11.9mSAR 13.2m
Gross profitSAR 20.8mSAR 24.9mSAR 19.2mSAR 18.9mSAR 15.8mSAR 10.5mSAR 7.1mSAR 5.2m
Operating incomeSAR 6.1mSAR 9.6mSAR 304,190SAR 6.6mSAR 7.3mSAR 4.6mSAR 2.6m−SAR 1.7m
Net incomeSAR 2.7mSAR 8.0mSAR 3.0mSAR 5.5mSAR 6.6mSAR 4.2mSAR 2.7m−SAR 2.0m
Diluted earnings per share0.050.150.060.100.120.080.05-0.04

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Total assetsSAR 132.3mSAR 102.8mSAR 94.5mSAR 63.2mSAR 57.3mSAR 35.5m——
Cash and short-term investments—SAR 6.4mSAR 18.8mSAR 3.3mSAR 3.5mSAR 3.6m——
Total liabilitiesSAR 67.2mSAR 41.8mSAR 26.5mSAR 15.8mSAR 15.7mSAR 13.7m——
DebtSAR 3.8mSAR 6.3mSAR 11.3mSAR 5.5mSAR 6.0mSAR 6.2mSAR 250,000—
Shareholders' equitySAR 65.1mSAR 61.0mSAR 68.1mSAR 47.4mSAR 41.6mSAR 21.9m——
Shares outstanding54m54m54m54m54m54m54m54m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations−SAR 5.6mSAR 393,205SAR 1.4mSAR 5.5m−SAR 4.9mSAR 387,588SAR 2.4m—
Capital spending−SAR 4.7m−SAR 4.1m−SAR 3.7m−SAR 5.1m−SAR 7.2m−SAR 3.0m——
Free cash flow−SAR 10.4m−SAR 3.7m−SAR 2.2mSAR 355,564−SAR 12.2m−SAR 2.6mSAR 2.4m—

Latest quarters

By quarter end

Jun 2025Dec 2024Jun 2024Dec 2023Jun 2023
RevenueSAR 47.7mSAR 50.4mSAR 33.7mSAR 27.0mSAR 21.7m
Gross profitSAR 12.5mSAR 13.4mSAR 11.2mSAR 12.1mSAR 8.1m
Operating incomeSAR 3.4mSAR 13.4mSAR 4.3mSAR 732,000SAR 3.8m
Net incomeSAR 2.0mSAR 4.8mSAR 3.2m−SAR 49,100SAR 3.1m
Diluted earnings per share0.040.090.06-0.010.05
Cash from operations−SAR 13.0mSAR 3.0m−SAR 3.0m——
Capital spending−SAR 2.0m−SAR 2.0m−SAR 1.0m——
Free cash flow−SAR 15.0mSAR 1.0m−SAR 4.0m——
Total assetsSAR 120.6mSAR 102.8mSAR 100.3m——
Cash and short-term investmentsSAR 2.1mSAR 6.4mSAR 8.2m——
DebtSAR 14.2mSAR 7.3mSAR 2.4m——
Shareholders' equitySAR 63.6mSAR 61.0mSAR 71.3m——

Growth per year

Compound annual rate

3 years5 years10 years
Revenue31.3%34.4%—
Operating income-2.4%5.6%—
Net income-21.1%-8.5%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin25.9%31.5%34.5%—
Operating margin8.9%8.5%10.8%—
Net margin6.1%7.2%9.4%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023
Price to earnings49.020.038.4
Price to sales1.41.92.4

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 10-for-1 split · 13 Nov 2025
  • 3-for-2 split · 26 Mar 2025

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.